MSK Report News

Wednesday, July 29, 2009 Arthritis: TNF Inhibitors Have Different TB Risks
The risk of developing tuberculosis is 7 to 17 fold higher among patients receiving anti-TNF monoclonal antibody therapy than for those receiving soluble TNF receptors. How can you protect your patients?...

Tuesday, July 28, 2009 Arthritis: Surprise: OA Not linked to Menopause
OA incidence rises with age in women, but not because of changes in female hormone levels...

Friday, July 24, 2009 Arthritis: Most OA Responses to Coxibs Show In First 2 Weeks
If OA patients do not respond to NSAID treatment by 2 weeks, it might be time to try a different drug...

Thursday, July 23, 2009 Arthritis: Gene Therapy Cleared in RA Patient Death
The vector used in an RA gene therapy study did not cause the death of a patient who died during the trial...

Thursday, July 23, 2009 Arthritis: New Anti-TNF Adverse Effect: Sarcoid-like Granuloma
Sarcoid-like granulomas are a newly identified adverse effect associated with all types of TNF-blockade...

Tuesday, July 21, 2009 BioPharm Business News and Perspectives: Belimumab Meets Lupus Phase 3 Endpoint
Benlysta^® (belimumab, formerly LymphoStat-B) was significantly better that standard care in the phase 3 BLISS-52 trial...

Friday, July 17, 2009 Consumer News: Excess Weight Speeds Up Osteoarthritis
Being overweight can cause a rapid deterioration of knee cartilage, leading to the development of osteoarthritis...

Thursday, July 16, 2009 Procedures: Tubular Diskectomy Patients Don't Recover Faster
Recovery from minimally invasive tubular diskectomy for sciatica is no quicker than from conventional microdiskectomy...

Thursday, July 16, 2009 Arthritis: Hand BMD Predicts RA Mortality
Hand bone mineral density measured by digital X-ray radiogrammetry may help doctors better predict risk of joint damage and mortality among individuals with RA...

Thursday, July 16, 2009 BioPharm Business News and Perspectives: Array BioPharma Stops Work on ARRY-797 Pan-Cytokine Inhibitor for RA Despite Good Early Data
The pan-cytokine inhibitor ARRY-797 was safe at doses of up to 1,200 mg/day in a phase 1 dose-escalation study in RA patients, but will not be developed further for use in RA...